The Impact of Protein Support on Weight Loss, Sarcopenia, and Quality of Life After Sleeve Gastrectomy

Güneş, Yasin; KaripBora,; ErginAnıl,; BulutNuriye, Esen; Mahir, FersahoğluMehmet; MemişoğluKemal,

doi:10.1089/bari.2018.0057

Cited by 6 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 70 trials with 3402 participants (mean age 54.6 years), were included in the data synthesis ( Table S1 ) 15–73 . These included six trials 18 , 38 , 41 in general surgery, three 34 , 54 , 59 in bariatric surgery, three 15 , 17 in breast cancer surgery, eleven 16 , 23 , 31 , 32 , 47 , 48 , 50 , 65 , 70 , 73 in cardiothoracic surgery, forty-one 19–21 , 24 , 26–30 , 33 , 35–37 , 39 , 40 , 43 , 45 , 49 , 51–53 , 55 , 57 , 58 , 60–64 , 66–69 , 71 , 72 in orthopaedics, three 42 , 44 , 46 in transplant surgery, one 56 in urology, one 25 in gynaecological surgery, and one 22 in trauma surgery. Some papers reported results of trial with multiple treatment arms: for the purpose of the meta-analysis, each treatment arm has been considered as a separate trial.…”

Section: Resultsmentioning

confidence: 99%

Interventions to prevent and treat sarcopenia in a surgical population: a systematic review and meta-analysis

2021

View full text Add to dashboard Cite

Background The aim of this systematic review was to summarize the results of trials evaluating interventions for the reduction of sarcopenia in patients undergoing surgery. Methods Searches were conducted using the Cochrane Central Register of Controlled Trials, MEDLINE and Embase. RCTs evaluating exercise, dietary or pharmacological interventions to address sarcopenia in the perioperative period were included. Treatment effect estimates were expressed as standardized mean differences (MDs) with confidence intervals, and heterogeneity was expressed as I2 values. Results Seventy trials including 3402 participants were selected for the data synthesis. Exercise interventions significantly increased muscle mass (MD 0.62, 95 per cent c.i. 0.34 to 0.90; P < 0.001), muscle strength (MD 0.55, 0.39 to 0.71; P < 0.001), measures of gait speed (MD 0.42, 0.05 to 0.79; P = 0.03), and reduced time for completion of set exercises (MD −0.76, −1.12 to −0.40; P < 0.001) compared with controls. Subgroup analysis showed that interventions in the early postoperative period were more likely to have a positive effect on muscle mass (MD 0.71, 0.35 to 1.07; P < 0.001) and timed tests (MD −0.70, −1.10 to −0.30; P = 0.005) than preoperative interventions. Treatment effects on muscle mass (MD 0.09, −0.31 to 0.49; P = 0.66) and strength (MD 0.46, −0.01 to 0.92; P = 0.05) were attenuated by the presence of cancer. Results of analyses restricted to nine trials at low risk of allocation concealment bias and fourteen trials at low risk of attrition bias were comparable to those of the primary analysis. Risk-of-bias assessment showed that most trials were at high risk of incomplete outcome and attrition bias, thus reducing the estimate of certainty of the evidence according to the GRADE assessment tool. Conclusion Exercise interventions appear beneficial in reducing the impact of sarcopenia. Because of the high risk of bias and low certainty of the current evidence, large RCTs using standardized measures of muscle mass should be undertaken.

show abstract